Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
Anne Lingford‐Hughes, S. Welch, Lesley Peters, et al.
Journal of Psychopharmacology (2012) Vol. 26, Iss. 7, pp. 899-952
Open Access | Times Cited: 303

Showing 1-25 of 303 citing articles:

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
GM Goodwin, Peter Haddad, I. Nicol Ferrier, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 6, pp. 495-553
Open Access | Times Cited: 1197
The dopamine theory of addiction: 40 years of highs and lows
David Nutt, Anne Lingford‐Hughes, David Erritzøe, et al.
Nature reviews. Neuroscience (2015) Vol. 16, Iss. 5, pp. 305-312
Closed Access | Times Cited: 611
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
David S. Baldwin, Ian Anderson, David Nutt, et al.
Journal of Psychopharmacology (2014) Vol. 28, Iss. 5, pp. 403-439
Open Access | Times Cited: 605
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes, Richard Drake, Carol Paton, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 3-78
Open Access | Times Cited: 503
Treatment of Benzodiazepine Dependence
Michael Soyka
New England Journal of Medicine (2017) Vol. 376, Iss. 12, pp. 1147-1157
Closed Access | Times Cited: 365
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Stephen Cooper, Gavin P. Reynolds, TRE Barnes, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 8, pp. 717-748
Open Access | Times Cited: 240
British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017
R. Hamish McAllister‐Williams, David S. Baldwin, Roch Cantwell, et al.
Journal of Psychopharmacology (2017) Vol. 31, Iss. 5, pp. 519-552
Open Access | Times Cited: 221
Benzodiazepines: Risks and benefits. A reconsideration
David S. Baldwin, Katherine J. Aitchison, Alan N. Bateson, et al.
Journal of Psychopharmacology (2013) Vol. 27, Iss. 11, pp. 967-971
Closed Access | Times Cited: 211
The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?
Wayne Hall, Adrian Carter, Cynthia Forlini
The Lancet Psychiatry (2015) Vol. 2, Iss. 1, pp. 105-110
Closed Access | Times Cited: 209
Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the “Bernese method”
Marc Vogel, Robert Hämmig, Antje Kemter, et al.
Substance Abuse and Rehabilitation (2016) Vol. Volume 7, pp. 99-105
Open Access | Times Cited: 173
Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology
Jonathan Rogers, Mark Oldham, Gregory L. Fricchione, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 4, pp. 327-369
Open Access | Times Cited: 89
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 24
Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders
Noeline Latt, Glenys Dore
Internal Medicine Journal (2014) Vol. 44, Iss. 9, pp. 911-915
Open Access | Times Cited: 149
Ketamine for the treatment of addiction: Evidence and potential mechanisms
Ivan Ezquerra-Romano, Will Lawn, Evgeny Krupitsky, et al.
Neuropharmacology (2018) Vol. 142, pp. 72-82
Open Access | Times Cited: 127
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Henri‐Jean Aubin, Amandine Luquiens, Ivan Berlin
British Journal of Clinical Pharmacology (2013) Vol. 77, Iss. 2, pp. 324-336
Open Access | Times Cited: 124
Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study
Jo Kimber, Sarah Larney, Matthew Hickman, et al.
The Lancet Psychiatry (2015) Vol. 2, Iss. 10, pp. 901-908
Closed Access | Times Cited: 118
Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers
Inge Mick, Jim Myers, Anna Carolina Ramos, et al.
Neuropsychopharmacology (2015) Vol. 41, Iss. 7, pp. 1742-1750
Open Access | Times Cited: 107
Synthetic cannabinoid withdrawal: A new demand on detoxification services
Vicki F. H. Macfarlane, Grant Christie
Drug and Alcohol Review (2015) Vol. 34, Iss. 2, pp. 147-153
Closed Access | Times Cited: 102
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom
Matthew Hickman, Colin Steer, Kate Tilling, et al.
Addiction (2018) Vol. 113, Iss. 8, pp. 1461-1476
Open Access | Times Cited: 101
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder
Ben Sessa, Laurie Higbed, Steve O’Brien, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 375-383
Open Access | Times Cited: 97
Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records
John Macleod, Colin Steer, Kate Tilling, et al.
PLoS Medicine (2019) Vol. 16, Iss. 11, pp. e1002965-e1002965
Open Access | Times Cited: 77
Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review
Ray Alsuhaibani, Douglas C. Smith, Richard Lowrie, et al.
BMC Psychiatry (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 59
The clinical pharmacology of acamprosate
Nicola J. Kalk, Anne Lingford‐Hughes
British Journal of Clinical Pharmacology (2012) Vol. 77, Iss. 2, pp. 315-323
Open Access | Times Cited: 105
Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics
Emily C. Williams, Carol E. Achtmeyer, Jessica P. Young, et al.
Journal of General Internal Medicine (2017) Vol. 33, Iss. 3, pp. 258-267
Open Access | Times Cited: 85
Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision
Michael Soyka, Henry R. Kranzler, Victor Hesselbrock, et al.
The World Journal of Biological Psychiatry (2016) Vol. 18, Iss. 2, pp. 86-119
Closed Access | Times Cited: 73
Page 1 - Next Page

Scroll to top